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Nagasaki, and Kanagawa, JapanEpidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor (EGFR-TKI) gefitinib has dramatic efficacy in
more than 70% of advanced non–small cell lung cancers
with EGFR gene mutations.1 Some patients with inoperable
systemic non–small cell lung cancers demonstrate a down-
staging of their cancer to operable disease status after gefiti-
nib treatment. Despite high response rates for EGFR mutant
tumors, the median time to progression is about 1 year.1 The
EGFR T790M mutation and MET amplification are thought
to be the underlying mechanisms of the acquired resistance
to EGFR-TKIs. When complete resection of residual disease
is possible, the patients can then be considered disease free.
We have aggressively performed salvage lung resections for
patients with gefitinib responses and demonstrated down-
staging to N0M0. The purpose of this study was to assessFIGURE 1. A, Overall survival curve of patients who underwent surgical
resection after response to gefitinib administration. Median overall survival
after surgery was 32 months. B, Recurrence-free survival curve of patients
who underwent surgical resection after response to gefitinib administration.
Median recurrence-free survival after surgery was 6 months.
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TABLE 1. Patient characteristics
Case Age (y), sex Initial CS Treatment before gefitinib (response)
Gefitinib
duration
CS before
surgery
1 73, F cT4(PM)N2M0, IIIB None 3 mo cT2N0M0, IB
2 51, F cT2N3M1(brain), IV None 3 y cT1N0M0, IA (local regrowth)
3 58, F cT2N2M0, IIIA CDDPþVNR (SD), CBDCAþPTX (SD) 5 mo cT1N0M0, IA
4 58, F cT4(Dþ)N0M0, IIIB CDDPþGEM (SD) 2 y, 10 mo cT1N0M0, IA (local regrowth)
5 63, F cT2N3M1(abd LN), IV CDDPþTS-1 (PR) 1 y, 4 mo cT1N0M0, IA (local regrowth)
6 33, M cT4 (PM, Eþ)N0M0, IIIB CBDCAþPTX (SD) 2 mo cT1N0M0, IA
7 54, M cT4N3M1(PM), IV CDDPþDTX (SD) 1 y, 10 mo cT1N0M0, IA
8 71, F cT2N3M0, IIIB None 1 y, 6 mo cT2N0M0, IB
9 57, F cT4N0M1(PM), IV CBDCAþDTX (SD) Unknown cT1N0M0, IA
CS, Clinical stage; EGFR, epidermal growth factor receptor; PM, pulmonary metastasis; DWD, died with disease; AWD, alive with disease; CDDP, cisplatin; VNR, vinorelbine
tartrate; SD, stable disease; CBDCA, carboplatin; PTX, paclitaxel; CR, complete response; D, pleural dissemination; GEM, gemcitabine; AWOD, alive without disease; abd LN,
abdominal lymph node; TS-1, tegafur/gimeracil/oteracil potassium; PR, partial response; E, malignant pleural effusion; DTX, docetaxel. *. Endothelial growth factor receptor
mutational analysis was performed on pretreatment biopsy specimens obtained by bronchoscopy.
Brief Clinical Reportsthe perioperative safety and survival benefit of these salvage
lung resections.
CLINICAL SUMMARY
After institutional review board approval at each institu-
tion, the clinicopathologic profiles of a total of 9 patients
were collected by a questionnaire survey in 2009 from 7 in-
stitutions belonging to the Lung Cancer Surgical Study
Group of the Japan Clinical Oncology Group. The question-
naire included the following items: sex, age, smoking
history, clinical (pretreatment) stage, response to therapy
before gefitinib monotherapy, response to and adverse
effects of gefitinib monotherapy, duration of gefitinib
administration, withdrawal period of gefitinib before sur-
gery, preoperative clinical stage, surgical procedure, morbid-
ity and mortality of surgery, primary site by lobe, histology,
pathologic stage, EGFR mutation status, postoperative ther-
apy, survival time, recurrence, and cause of death.
The patient characteristics are shown in Table 1. All cases
were adenocarcinoma, and all had been initially diagnosed as
inoperable. Surgery was performed to eradicate residual tu-
mors or local recurrence and regrowth, with a median admin-
istration period of 17 months (range, 2–36 months). Gefitinib
was terminated before surgery in all cases,with amedianwith-
drawal period of 7 days (range, 1–21 days). Resection was ac-
complished in all cases, with a median hospital stay of 9 days
(range, 6–34 days). There was 1 case of mild liver dysfunc-
tion, and there were no deaths. An EGFR mutational analysis
of resected specimens or of the pretreatment biopsy specimen
(patient 3)was performed in 7 cases. Six of 7 patients harbored
EGFR mutations, exon 19 deletions or exon 21 L858R. Two
patients also had EGFR-TKI–resistant exon 20 T790Mmuta-
tions. Four patients who underwent surgery in late study pe-
riod received gefitinib postoperatively for various durations.
Despite the remarkable downstaging of the patients’ diseasee70 The Journal of Thoracic and Cardiovascular Surgafter gefitinib treatment, 7 of 9 patients showed a more ad-
vanced pathologic stage than their preoperative clinical stage.
Six patients with initial N2-3 disease all had radiologic down-
staging to N0 status before attempted resection. Pathologi-
cally, 2 patients had persistent N2 disease and 1 had N1
disease. The recurrence-free and overall survivals are shown
in Figure 1 (A and B). The most common site of recurrence
was the brain. One patient has been alive without disease
for 11 months with the use of adjuvant gefitinib.
DISCUSSION
Our patient population had no serious immediate
postoperative morbidity or mortality. Among a total of 41 pa-
tients in the literature who underwent lung resection after
EGFR-TKI treatment, none died perioperatively.2-5 Although
there has been some concern that preoperative EGFR-TKIs
may be associated with impaired wound healing, major
lung resection after EGFR-TKI therapy may be feasible.
On the other hand, postoperative survival in the this series
was not satisfactory, with a median recurrence-free survival
of 6 months. Despite dramatic radiographic downstaging af-
ter gefitinib treatment, 7 of 9 patients had further advanced
pathologic stages than their preoperative clinical stages.
Dramatic radiologic response does not necessarily correlate
with cell death. Our results suggest that initially expressed
systemic disease was essentially unchanged even after dra-
matic radiologic response to gefitinib. Surgery after gefitinib
treatment should be limited to patients without initial evi-
dence of disseminated and distant metastases. EGFR-TKIs
have both higher and more rapid responses, and better toxic-
ity profiles than standard chemotherapy for non–small cell
lung cancers harboring EGFR mutation. Preoperative
EGFR-TKI treatment strategy should be reevaluated in the
neoadjuvant setting for early to locally advanced but opera-
ble disease. The optimal duration of EGFR-TKI treatment,ery c November 2010
Mode of resection Pathologic stage EGFR gene status
Adjuvant
therapy Outcome
Lobectomy pT2N1M0, IIB Wild type None Bone metastasis (6 mo), DWD (1 y, 5 mo)
Lobectomy pT1N0M0, IA Exon 19 (del) None Brain metastasis (2 mo), AWD (3 y, 6 mo)
Left pneumonectomy Pathologic CR Exon 19 (del)* Gefitinib (2 y) Brain metastasis (2 y, 4 mo), AWD (2 y, 7 mo)
Bilobectomy pT1N1M0, IIA Exon 19 (del) Gefitinib (11 mo) AWOD (11 mo)
Lobectomy pT1N2M0, IIIA Unknown None Brain metastasis (5 mo), AWD (2 y)
Left extrapleural
pneumonectomy
pT4N2M0, IIIB Exon 19 (del) Gefitinib (3 mo) Brain metastasis (3 mo), DWD (1 y, 7 mo)
Lobectomy pT4N0M0, IIIB Exon 19 (del)
Exon 20 (T790M)
None Metastasis in thorax (6 mo), AWD (10 mo)
Lobectomy pT2N2M0, IIIA Exon 21 (L858R)
Exon 20 (T790M)
None Metastasis in thorax (4 mo), DWD (1 y, 9 mo)
Lobectomy pT2N0M0, IB Unknown Gefitinib Unknown
TABLE 1. Continued
Brief Clinical Reportsthe timing of surgery, and the role of adjuvant EGFR-TKI
treatment should be also investigated in the future.
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Fallot repairIgor E. Konstantinov, MD, PhD,a, Tyson A. Fricke, BMedSci,a Yves d’Udekem, MD, PhD,a and
Terry Robertson, MBBS, FRACP,b Melbourne and Adelaide, AustraliaAortic dissection in children and adolescents is rare, yet it
is associated with high mortality. A recent article1 describ-
ing 13 patients with aortic dissections operated between
1970 and 2000 reported an operative mortality of 38%.
Progressive aortic root dilatation is a recognized feature
of tetralogy of Fallot (TOF)2,3 and generally managed con-
servatively. However, 2 recent reports of aortic dissection
in patients with aortic aneurysm after TOF repair4,5 to-
gether with the case presented reemphasize the fact that
aortic root dilatation must be monitored closely in patients
with TOF.rdiovascular Surgery c Volume 140, Number 5 e71
